{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,27]],"date-time":"2026-06-27T23:31:51Z","timestamp":1782603111322,"version":"3.54.5"},"reference-count":91,"publisher":"IMR Press","issue":"1","license":[{"start":{"date-parts":[[2022,1,28]],"date-time":"2022-01-28T00:00:00Z","timestamp":1643328000000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J. Integr. Neurosci."],"abstract":"<jats:p>Botulinum toxin (BT) is a neurotoxin produced by Clostridium botulinum, a gram-positive anaerobic bacterium. Systemic human intoxication from BT following oral ingestion results in acute and life-threatening muscle paralysis called botulism. BT has a wide scope of therapeutic uses, including conditions associated with increased muscle tone, smooth muscle hyperactivity, salivation, sweating, and allergies, as well as for cosmetic purposes. Several commercial forms of BT are available for medical use, including Botox (onabotulinumtoxinA). Multiple studies have found evidence of an analgesic effect of onabotulinumtoxinA and demonstrated the benefits of its use for the treatment of various chronic pain disorders. In this review, we provide an update on the use of onabotulinumtoxinA for the treatment of headache disorders.<\/jats:p>","DOI":"10.31083\/j.jin2101037","type":"journal-article","created":{"date-parts":[[2022,1,29]],"date-time":"2022-01-29T11:28:26Z","timestamp":1643455706000},"source":"Crossref","is-referenced-by-count":6,"title":["OnabotulinumtoxinA for the treatment of headache: an updated review"],"prefix":"10.31083","volume":"21","author":[{"given":"Joseph H.","family":"Talbet","sequence":"first","affiliation":[{"name":"College of Medicine, Howard University, 20059 Washington, D.C., USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayman G.","family":"Elnahry","sequence":"first","affiliation":[{"name":"Department of Ophthalmology, Faculty of Medicine, Cairo University, 11956 Cairo, Egypt"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"16242","published-online":{"date-parts":[[2022,1,28]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","unstructured":"Ashkenazi A, Blumenfeld A. OnabotulinumtoxinA for the Treatment of Headache. Headache. 2013; 53: 54\u201361.","DOI":"10.1111\/head.12185"},{"key":"ref2","doi-asserted-by":"crossref","unstructured":"Silberstein SD. The Use of Botulinum Toxin in the Management of Headache Disorders. Seminars in Neurology. 2016; 36: 92\u201398.","DOI":"10.1055\/s-0036-1571443"},{"key":"ref3","unstructured":"Dhaked RK, Singh MK, Singh P, Gupta P. Botulinum toxin: bioweapon & magic drug. The Indian Journal of Medical Research. 2010; 132: 489\u2013503."},{"key":"ref4","doi-asserted-by":"crossref","unstructured":"Nigam PK, Nigam A. Botulinum toxin. Indian Journal of Dermatology. 2010; 55: 8\u201314.","DOI":"10.4103\/0019-5154.60343"},{"key":"ref5","doi-asserted-by":"crossref","unstructured":"Awan KH. The therapeutic usage of botulinum toxin (Botox) in non-cosmetic head and neck conditions\u2014an evidence based review. Saudi Pharmaceutical Journal. 2017; 25: 18\u201324.","DOI":"10.1016\/j.jsps.2016.04.024"},{"key":"ref6","doi-asserted-by":"crossref","unstructured":"Sandrini G, De Icco R, Tassorelli C, Smania N, Tamburin S. Botulinum neurotoxin type a for the treatment of pain: not just in migraine and trigeminal neuralgia. The Journal of Headache and Pain. 2017; 18: 38.","DOI":"10.1186\/s10194-017-0744-z"},{"key":"ref7","doi-asserted-by":"crossref","unstructured":"Ahmed F. Headache disorders: differentiating and managing the common subtypes. British Journal of Pain. 2012; 6: 124\u2013132.","DOI":"10.1177\/2049463712459691"},{"key":"ref8","doi-asserted-by":"crossref","unstructured":"Saltvig I, Matzen SH. Incidental Treatment of a Subclinical Chronic Tension-Type Headache by Cosmetic Use of Botulinum Toxin a: a Case Report. Case Reports in Dermatology. 2017; 9: 249\u2013253.","DOI":"10.1159\/000484657"},{"key":"ref9","doi-asserted-by":"crossref","unstructured":"Headache Classification Committee of the International Headache Society (IHS). The International Classification of Headache Disorders, 3rd edition (beta version). Cephalalgia.2013; 33: 629\u2013808.","DOI":"10.1177\/0333102413485658"},{"key":"ref10","doi-asserted-by":"crossref","unstructured":"Finkel AG. Botulinum Toxin and the Treatment of Headache: a Clinical Review. Headache. 2011; 51: 1565\u20131572.","DOI":"10.1111\/j.1526-4610.2011.02021.x"},{"key":"ref11","doi-asserted-by":"crossref","unstructured":"Bendtsen L, Sacco S, Ashina M, Mitsikostas D, Ahmed F, Pozo-Rosich P, et al. Guideline on the use of onabotulinumtoxinA in chronic migraine: a consensus statement from the European Headache Federation. The Journal of Headache and Pain. 2018; 19: 91.","DOI":"10.1186\/s10194-018-0921-8"},{"key":"ref12","doi-asserted-by":"crossref","unstructured":"Goldman ND, Dorton LH, Marcum KK, Gilbert RM, Sandoval LF. Evaluation of headache relief with cosmetic onabotulinumtoxinA injections. Journal of Cosmetic Dermatology. 2014; 13: 224\u2013231.","DOI":"10.1111\/jocd.12098"},{"key":"ref13","doi-asserted-by":"crossref","unstructured":"Becker WJ. Botulinum Toxin in the Treatment of Headache. Toxins. 2020; 12: 803.","DOI":"10.3390\/toxins12120803"},{"key":"ref14","doi-asserted-by":"crossref","unstructured":"Escher CM, Paracka L, Dressler D, Kollewe K. Botulinum toxin in the management of chronic migraine: clinical evidence and experience. Therapeutic Advances in Neurological Disorders. 2017; 10: 127\u2013135.","DOI":"10.1177\/1756285616677005"},{"key":"ref15","doi-asserted-by":"crossref","unstructured":"Schroeder AS, Huss K, Blaschek A, Koerte IK, Zeycan B, Roser T, et al. Ten-year follow-up in a case series of integrative botulinum toxin intervention in adolescents with chronic daily headache and associated muscle pain. Neuropediatrics. 2012; 43: 339\u2013345.","DOI":"10.1055\/s-0032-1329612"},{"key":"ref16","doi-asserted-by":"crossref","unstructured":"Zhang H, Zhang H, Wei Y, Lian Y, Chen Y, Zheng Y. Treatment of chronic daily headache with comorbid anxiety and depression using botulinum toxin a: a prospective pilot study. International Journal of Neuroscience. 2017; 127: 285\u2013290.","DOI":"10.1080\/00207454.2016.1196687"},{"key":"ref17","doi-asserted-by":"crossref","unstructured":"Hepp Z, Rosen NL, Gillard PG, Varon SF, Mathew N, Dodick DW. Comparative effectiveness of onabotulinumtoxinA versus oral migraine prophylactic medications on headache-related resource utilization in the management of chronic migraine: Retrospective analysis of a us-based insurance claims database. Cephalalgia. 2016; 36: 862\u2013874.","DOI":"10.1177\/0333102415621294"},{"key":"ref18","doi-asserted-by":"crossref","unstructured":"Hollier-Hann G, Curry A, Onishchenko K, Akehurst R, Ahmed F, Davies B, et al. Updated cost-effectiveness analysis of onabotulinumtoxinA for the prevention of headache in adults with chronic migraine who have previously received three or more preventive treatments in the UK. Journal of Medical Economics. 2020; 23: 113\u2013123.","DOI":"10.1080\/13696998.2019.1675417"},{"key":"ref19","doi-asserted-by":"crossref","unstructured":"Gandolfi M, Donisi V, Marchioretto F, Battista S, Smania N, Del Piccolo L. A Prospective Observational Cohort Study on Pharmacological Habitus, Headache-Related Disability and Psychological Profile in Patients with Chronic Migraine Undergoing OnabotulinumtoxinA Prophylactic Treatment. Toxins. 2019; 11: 504.","DOI":"10.3390\/toxins11090504"},{"key":"ref20","doi-asserted-by":"crossref","unstructured":"MacGregor EA, Brandes J, Eikermann A, Giammarco R. Impact of migraine on patients and their families: the Migraine and Zolmitriptan Evaluation (MAZE) survey\u2013Phase III. Current Medical Research and Opinion. 2004; 20: 1143\u20131150.","DOI":"10.1185\/030079904125004178"},{"key":"ref21","doi-asserted-by":"crossref","unstructured":"Filipovi\u0107 B, de Ru JA, Hakim S, van de Langenberg R, Borggreven PA, Lohuis PJFM. Treatment of Frontal Secondary Headache Attributed to Supratrochlear and Supraorbital Nerve Entrapment with Oral Medication or Botulinum Toxin Type a vs Endoscopic Decompression Surgery. JAMA Facial Plastic Surgery. 2018; 20: 394\u2013400.","DOI":"10.1001\/jamafacial.2018.0268"},{"key":"ref22","doi-asserted-by":"crossref","unstructured":"Wu-Fienberg Y, Ansari H, Zardouz S, Narouze S, Blaha T, Swanson M, et al. Anatomical Look into OnabotulinumtoxinA Injection for Chronic Migraine Headache. Regional Anesthesia and Pain Medicine. 2018; 43: 869\u2013874.","DOI":"10.1097\/AAP.0000000000000818"},{"key":"ref23","doi-asserted-by":"crossref","unstructured":"Becker WJ, Chitsantikul P. Cervicogenic headache and onabotulinumtoxinA: where do we stand? Cephalalgia. 2011; 31: 979\u2013980.","DOI":"10.1177\/0333102411410086"},{"key":"ref24","doi-asserted-by":"crossref","unstructured":"Choi Y, Lee W, Lee H, Lee K, Kim H, Hu K. Effective Botulinum Toxin Injection Guide for Treatment of Temporal Headache. Toxins. 2016; 8: 265.","DOI":"10.3390\/toxins8090265"},{"key":"ref25","doi-asserted-by":"crossref","unstructured":"Kim YG, Bae JH, Kim H, Wang SJ, Kim ST. A Proposal for Botulinum Toxin Type A Injection Into the Temporal Region in Chronic Migraine Headache. Toxins. 2020; 12: 214.","DOI":"10.3390\/toxins12040214"},{"key":"ref26","doi-asserted-by":"crossref","unstructured":"Janis JE, Hatef DA, Ducic I, Reece EM, Hamawy AH, Becker S, et al. The Anatomy of the Greater Occipital Nerve: Part II. Compression Point Topography. Plastic and Reconstructive Surgery. 2010; 126: 1563\u20131572.","DOI":"10.1097\/PRS.0b013e3181ef7f0c"},{"key":"ref27","doi-asserted-by":"crossref","unstructured":"Blumenfeld A, Silberstein SD, Dodick DW, Aurora SK, Turkel CC, Binder WJ. Method of injection of onabotulinumtoxinA for chronic migraine: a safe, well-tolerated, and effective treatment paradigm based on the PREEMPT clinical program. Headache. 2010; 50: 1406\u20131418.","DOI":"10.1111\/j.1526-4610.2010.01766.x"},{"key":"ref28","doi-asserted-by":"crossref","unstructured":"Aurora S, Dodick D, Turkel C, DeGryse R, Silberstein S, Lipton R, et al. OnabotulinumtoxinA for treatment of chronic migraine: Results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 1 trial. Cephalalgia. 2010; 30: 793\u2013803.","DOI":"10.1177\/0333102410364676"},{"key":"ref29","doi-asserted-by":"crossref","unstructured":"Diener HC, Dodick DW, Aurora SK, Turkel CC, DeGryse RE, Lipton RB, et al. OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 2 trial. Cephalalgia. 2010; 30: 804\u2013814.","DOI":"10.1177\/0333102410364677"},{"key":"ref30","doi-asserted-by":"crossref","unstructured":"Gerwin R. Treatment of chronic migraine headache with onabotulinumtoxinA. Current Pain and Headache Reports. 2011; 15: 336\u2013338.","DOI":"10.1007\/s11916-011-0202-6"},{"key":"ref31","doi-asserted-by":"crossref","unstructured":"Russo M, Manzoni GC, Taga A, Genovese A, Veronesi L, Pasquarella C, et al. The use of onabotulinum toxin a (Botox\u00ae) in the treatment of chronic migraine at the Parma Headache Centre: a prospective observational study. Neurological Sciences. 2016; 37: 1127\u20131131.","DOI":"10.1007\/s10072-016-2568-z"},{"key":"ref32","doi-asserted-by":"crossref","unstructured":"Janis JE, Barker JC, Palettas M. Targeted Peripheral Nerve-directed Onabotulinumtoxin A Injection for Effective Long-term Therapy for Migraine Headache. Plastic and Reconstructive Surgery. Global Open. 2017; 5: e1270.","DOI":"10.1097\/GOX.0000000000001270"},{"key":"ref33","doi-asserted-by":"crossref","unstructured":"Janis JE, Dhanik A, Howard JH. Validation of the peripheral trigger point theory of migraine headaches: single-surgeon experience using botulinum toxin and surgical decompression. Plastic and Reconstructive Surgery. 2011; 128: 123\u2013131.","DOI":"10.1097\/PRS.0b013e3182173d64"},{"key":"ref34","doi-asserted-by":"crossref","unstructured":"Schoenbrunner AR, Khansa I, Janis JE. Cost-Effectiveness of Long-Term, Targeted OnabotulinumtoxinA versus Peripheral Trigger Site Deactivation Surgery for the Treatment of Refractory Migraine Headaches. Plastic & Reconstructive Surgery. 2020; 145: 401e\u2013406e.","DOI":"10.1097\/PRS.0000000000006480"},{"key":"ref35","doi-asserted-by":"crossref","unstructured":"Batty AJ, Hansen RN, Bloudek LM, Varon SF, Hayward EJ, Pennington BW, et al. The cost-effectiveness of onabotulinumtoxinA for the prophylaxis of headache in adults with chronic migraine in the UK. Journal of Medical Economics. 2013; 16: 877\u2013887.","DOI":"10.3111\/13696998.2013.802694"},{"key":"ref36","doi-asserted-by":"crossref","unstructured":"Kollewe K, Gaul C, Gendolla A, Sommer K. Real-life use of onabotulinumtoxinA reduces healthcare resource utilization in individuals with chronic migraine: the REPOSE study. The Journal of Headache and Pain. 2021; 22: 50.","DOI":"10.1186\/s10194-021-01260-4"},{"key":"ref37","doi-asserted-by":"crossref","unstructured":"Hansson-Hedblom A, Axelsson I, Jacobson L, Tedroff J, Borgstr\u00f6m F. Economic consequences of migraine in Sweden and implications for the cost-effectiveness of onabotulinumtoxinA (Botox) for chronic migraine in Sweden and Norway. The Journal of Headache and Pain. 2020; 21: 99.","DOI":"10.1186\/s10194-020-01162-x"},{"key":"ref38","doi-asserted-by":"crossref","unstructured":"Torres-Ferrus M, Gallardo VJ, Alpuente A, Pozo-Rosich P. Influence of headache pain intensity and frequency on migraine-related disability in chronic migraine patients treated with OnabotulinumtoxinA. The Journal of Headache and Pain. 2020; 21: 88.","DOI":"10.1186\/s10194-020-01157-8"},{"key":"ref39","doi-asserted-by":"crossref","unstructured":"Ornello R, Guerzoni S, Baraldi C, Evangelista L, Frattale I, Marini C, et al. Sustained response to onabotulinumtoxin a in patients with chronic migraine: real-life data. The Journal of Headache and Pain. 2020; 21: 40.","DOI":"10.1186\/s10194-020-01113-6"},{"key":"ref40","doi-asserted-by":"crossref","unstructured":"Young WB, Ivan Lopez J, Rothrock JF, Orejudos A, Manack Adams A, Lipton RB, et al. Effects of onabotulinumtoxinA treatment in chronic migraine patients with and without daily headache at baseline: results from the COMPEL Study. The Journal of Headache and Pain. 2019; 20: 12.","DOI":"10.1186\/s10194-018-0953-0"},{"key":"ref41","doi-asserted-by":"crossref","unstructured":"Young WB, Ivan Lopez J, Rothrock JF, Orejudos A, Manack Adams A, Lipton RB, et al. Effects of onabotulinumtoxinA treatment in patients with and without allodynia: results of the COMPEL study. The Journal of Headache and Pain. 2019; 20: 10.","DOI":"10.1186\/s10194-018-0952-1"},{"key":"ref42","doi-asserted-by":"crossref","unstructured":"Silberstein SD, Diener H, Dodick DW, Manack Adams A, DeGryse RE, Lipton RB. The Impact of OnabotulinumtoxinA vs. Placebo on Efficacy Outcomes in Headache Day Responder and Nonresponder Patients with Chronic Migraine. Pain and Therapy. 2020; 9: 695\u2013707.","DOI":"10.1007\/s40122-020-00199-9"},{"key":"ref43","doi-asserted-by":"crossref","unstructured":"Diener H, Dodick DW, Lipton RB, Manack Adams A, DeGryse RE, Silberstein SD. Benefits beyond Headache Days with OnabotulinumtoxinA Treatment: a Pooled PREEMPT Analysis. Pain and Therapy. 2020; 9: 683\u2013694.","DOI":"10.1007\/s40122-020-00198-w"},{"key":"ref44","doi-asserted-by":"crossref","unstructured":"Schulman E, McGeeney BE. Current concepts in refractory migraine. Current Treatment Options in Neurology. 2013; 15: 40\u201355.","DOI":"10.1007\/s11940-012-0206-5"},{"key":"ref45","doi-asserted-by":"crossref","unstructured":"Silberstein SD, Blumenfeld AM, Cady RK, Turner IM, Lipton RB, Diener H, et al. OnabotulinumtoxinA for treatment of chronic migraine: PREEMPT 24-week pooled subgroup analysis of patients who had acute headache medication overuse at baseline. Journal of the Neurological Sciences. 2013; 331: 48\u201356.","DOI":"10.1016\/j.jns.2013.05.003"},{"key":"ref46","doi-asserted-by":"crossref","unstructured":"Blumenfeld AM, Patel AT, Turner IM, Mullin KB, Manack Adams A, Rothrock JF. Patient-Reported Outcomes from a 1-Year, Real-World, Head-to-Head Comparison of OnabotulinumtoxinA and Topiramate for Headache Prevention in Adults with Chronic Migraine. Journal of Primary Care & Community Health. 2020; 11: 2150132720959936.","DOI":"10.1177\/2150132720959936"},{"key":"ref47","doi-asserted-by":"crossref","unstructured":"Rothrock JF, Adams AM, Lipton RB, Silberstein SD, Jo E, Zhao X, et al. FORWARD Study: Evaluating the Comparative Effectiveness of OnabotulinumtoxinA and Topiramate for Headache Prevention in Adults with Chronic Migraine. Headache. 2019; 59: 1700\u20131713.","DOI":"10.1111\/head.13653"},{"key":"ref48","doi-asserted-by":"crossref","unstructured":"Blumenfeld AM, Aurora SK, Laranjo K, Papapetropoulos S. Unmet clinical needs in chronic migraine: Rationale for study and design of COMPEL, an open-label, multicenter study of the long-term efficacy, safety, and tolerability of onabotulinumtoxinA for headache prophylaxis in adults with chronic migraine. BMC Neurology. 2015; 15: 100.","DOI":"10.1186\/s12883-015-0353-x"},{"key":"ref49","doi-asserted-by":"crossref","unstructured":"Boudreau GP, Grosberg BM, McAllister PJ, Lipton RB, Buse DC. Prophylactic onabotulinumtoxinA in patients with chronic migraine and comorbid depression: an open-label, multicenter, pilot study of efficacy, safety and effect on headache-related disability, depression, and anxiety. International Journal of General Medicine. 2015; 8: 79\u201386.","DOI":"10.2147\/IJGM.S70456"},{"key":"ref50","doi-asserted-by":"crossref","unstructured":"d\u2019Onofrio F, de Falco A, Costanzo A, Spitaleri D, Casucci G, Raimo S. Impulse control disorders in chronic migraine with medication overuse after onabotulinumtoxinA: a single-center prospective cohort study. Journal of Clinical Neuroscience. 2020; 80: 152\u2013155.","DOI":"10.1016\/j.jocn.2020.07.075"},{"key":"ref51","doi-asserted-by":"crossref","unstructured":"Kim CC, Bogart MM, Wee SA, Burstein R, Arndt KA, Dover JS. Predicting migraine responsiveness to botulinum toxin type a injections. Archives of Dermatology. 2010; 146: 159\u2013163.","DOI":"10.1001\/archdermatol.2009.356"},{"key":"ref52","doi-asserted-by":"crossref","unstructured":"Kabbouche M, O\u2019Brien H, Hershey AD. OnabotulinumtoxinA in Pediatric Chronic Daily Headache. Current Neurology and Neuroscience Reports. 2012; 12: 114\u2013117.","DOI":"10.1007\/s11910-012-0251-1"},{"key":"ref53","doi-asserted-by":"crossref","unstructured":"Wong H, Khalil M, Ahmed F. OnabotulinumtoxinA for chronic migraine during pregnancy: a real world experience on 45 patients. The Journal of Headache and Pain. 2020; 21: 129.","DOI":"10.1186\/s10194-020-01196-1"},{"key":"ref54","doi-asserted-by":"crossref","unstructured":"Negro A, Curto M, Lionetto L, Martelletti P. A two years open-label prospective study of OnabotulinumtoxinA 195 U in medication overuse headache: a real-world experience. The Journal of Headache and Pain. 2015; 17: 1.","DOI":"10.1186\/s10194-016-0591-3"},{"key":"ref55","doi-asserted-by":"crossref","unstructured":"Negro A, Curto M, Lionetto L, Crialesi D, Martelletti P. OnabotulinumtoxinA 155 U in medication overuse headache: a two years prospective study. SpringerPlus. 2015; 4: 826.","DOI":"10.1186\/s40064-015-1636-9"},{"key":"ref56","doi-asserted-by":"crossref","unstructured":"Sandrini G, Perrotta A, Tassorelli C, Torelli P, Brighina F, Sances G, et al. Botulinum toxin type-a in the prophylactic treatment of medication-overuse headache: a multicenter, double-blind, randomized, placebo-controlled, parallel group study. The Journal of Headache and Pain. 2011; 12: 427\u2013433.","DOI":"10.1007\/s10194-011-0339-z"},{"key":"ref57","doi-asserted-by":"crossref","unstructured":"Guerzoni S, Pellesi L, Baraldi C, Cainazzo MM, Negro A, Martelletti P, et al. Long-term Treatment Benefits and Prolonged Efficacy of OnabotulinumtoxinA in Patients Affected by Chronic Migraine and Medication Overuse Headache over 3\u2009Years of Therapy. Frontiers in Neurology. 2017; 8: 586.","DOI":"10.3389\/fneur.2017.00586"},{"key":"ref58","doi-asserted-by":"crossref","unstructured":"Matharu M, Halker R, Pozo-Rosich P, DeGryse R, Manack Adams A, Aurora SK. The impact of onabotulinumtoxinA on severe headache days: PREEMPT 56-week pooled analysis. The Journal of Headache and Pain. 2017; 18: 78.","DOI":"10.1186\/s10194-017-0784-4"},{"key":"ref59","doi-asserted-by":"crossref","unstructured":"Binder WJ, Brin MF, Blitzer A, Schoenrock LD, Pogoda JM. Botulinum toxin type a (BOTOX) for treatment of migraine headaches: an open-label study. Otolaryngology\u2014Head and Neck Surgery. 2000; 123: 669\u2013676.","DOI":"10.1067\/mhn.2000.110960"},{"key":"ref60","doi-asserted-by":"crossref","unstructured":"Silberstein S, Mathew N, Saper J, Jenkins S. Botulinum Toxin Type a as a Migraine Preventive Treatment. Headache. 2000; 40: 445\u2013450.","DOI":"10.1046\/j.1526-4610.2000.00066.x"},{"key":"ref61","doi-asserted-by":"crossref","unstructured":"Aurora SK, Gawel M, Brandes JL, Pokta S, Vandenburgh AM. Botulinum toxin type a prophylactic treatment of episodic migraine: a randomized, double-blind, placebo-controlled exploratory study. Headache. 2007; 47: 486\u2013499.","DOI":"10.1111\/j.1526-4610.2006.00624.x"},{"key":"ref62","doi-asserted-by":"crossref","unstructured":"Finkel AG. Botulinum toxin and the treatment of headache: a clinical review. Toxicon. 2015; 107: 114\u2013119.","DOI":"10.1016\/j.toxicon.2015.09.008"},{"key":"ref63","doi-asserted-by":"crossref","unstructured":"Shuhendler AJ, Lee S, Siu M, Ondovcik S, Lam K, Alabdullatif A, et al. Efficacy of Botulinum Toxin Type a for the Prophylaxis of Episodic Migraine Headaches: a Meta-analysis of Randomized, Double-Blind, Placebo-Controlled Trials. Pharmacotherapy. 2009; 29: 784\u2013791.","DOI":"10.1592\/phco.29.7.784"},{"key":"ref64","doi-asserted-by":"crossref","unstructured":"Luvisetto S, Gazerani P, Cianchetti C, Pavone F. Botulinum Toxin Type a as a Therapeutic Agent against Headache and Related Disorders. Toxins. 2015; 7: 3818\u20133844.","DOI":"10.3390\/toxins7093818"},{"key":"ref65","doi-asserted-by":"crossref","unstructured":"Simpson DM, Hallett M, Ashman EJ, Comella CL, Green MW, Gronseth GS, et al. Practice guideline update summary: Botulinum neurotoxin for the treatment of blepharospasm, cervical dystonia, adult spasticity, and headache. Neurology. 2016; 86: 1818\u20131826.","DOI":"10.1212\/WNL.0000000000002560"},{"key":"ref66","doi-asserted-by":"crossref","unstructured":"Elkind AH, O\u2019Carroll P, Blumenfeld A, DeGryse R, Dimitrova R. A series of three sequential, randomized, controlled studies of repeated treatments with botulinum toxin type a for migraine prophylaxis. The Journal of Pain. 2006; 7: 688\u2013696.","DOI":"10.1016\/j.jpain.2006.03.002"},{"key":"ref67","doi-asserted-by":"crossref","unstructured":"Relja M, Poole AC, Schoenen J, Pascual J, Lei X, Thompson C. A multicentre, double-blind, randomized, placebo-controlled, parallel group study of multiple treatments of botulinum toxin type a (BoNTA) for the prophylaxis of episodic migraine headaches. Cephalalgia. 2007; 27: 492\u2013503.","DOI":"10.1111\/j.1468-2982.2007.01315.x"},{"key":"ref68","doi-asserted-by":"crossref","unstructured":"Wieckiewicz M, Grychowska N, Zietek M, Wieckiewicz G, Smardz J. Evidence to Use Botulinum Toxin Injections in Tension-Type Headache Management: a Systematic Review. Toxins. 2017; 9: 370.","DOI":"10.3390\/toxins9110370"},{"key":"ref69","doi-asserted-by":"crossref","unstructured":"Pihut M, Ferendiuk E, Szewczyk M, Kasprzyk K, Wieckiewicz M. The efficiency of botulinum toxin type a for the treatment of masseter muscle pain in patients with temporomandibular joint dysfunction and tension-type headache. The Journal of Headache and Pain. 2016; 17: 29.","DOI":"10.1186\/s10194-016-0621-1"},{"key":"ref70","doi-asserted-by":"crossref","unstructured":"Harden RN, Cottrill J, Gagnon CM, Smitherman TA, Weinland SR, Tann B, et al. Botulinum Toxin a in the Treatment of Chronic Tension-Type Headache with Cervical Myofascial Trigger Points: a Randomized, Double-Blind, Placebo-Controlled Pilot Study. Headache. 2009; 49: 732\u2013743.","DOI":"10.1111\/j.1526-4610.2008.01286.x"},{"key":"ref71","doi-asserted-by":"crossref","unstructured":"Mizuma A, Nagata E, Yasuda T, Kouchi M, Nakayama T, Honma K, et al. Botulinum toxin a is effective to treat tension-type headache caused by hemifacial spasm. Journal of Clinical Neuroscience. 2017; 44: 284\u2013288.","DOI":"10.1016\/j.jocn.2017.06.069"},{"key":"ref72","doi-asserted-by":"crossref","unstructured":"Spears RC. Efficacy of botulinum toxin type a in new daily persistent headache. The Journal of Headache and Pain. 2008; 9: 405\u2013406.","DOI":"10.1007\/s10194-008-0078-y"},{"key":"ref73","doi-asserted-by":"crossref","unstructured":"Ali A, Kriegler J, Tepper S, Vij B. New Daily Persistent Headache and OnabotulinumtoxinA Therapy. Clinical Neuropharmacology. 2019; 42: 1\u20133.","DOI":"10.1097\/WNF.0000000000000313"},{"key":"ref74","doi-asserted-by":"crossref","unstructured":"Freund B, Kotchetkov I, Rao A. The Efficacy of Botulinum Toxin in Cluster Headache: a Systematic Review. Journal of Oral & Facial Pain and Headache. 2020; 34: 129\u2013134.","DOI":"10.11607\/ofph.2444"},{"key":"ref75","doi-asserted-by":"crossref","unstructured":"Lampl C, Rudolph M, Br\u00e4utigam E. OnabotulinumtoxinA in the treatment of refractory chronic cluster headache. The Journal of Headache and Pain. 2018; 19: 45.","DOI":"10.1186\/s10194-018-0874-y"},{"key":"ref76","doi-asserted-by":"crossref","unstructured":"Bratbak DF, Nordg\u00e5rd S, Stovner LJ, Linde M, Folvik M, Bugten V, et al. Pilot study of sphenopalatine injection of onabotulinumtoxinA for the treatment of intractable chronic cluster headache. Cephalalgia. 2016; 36: 503\u2013509.","DOI":"10.1177\/0333102415597891"},{"key":"ref77","doi-asserted-by":"crossref","unstructured":"Sostak P, Krause P, F\u00f6rderreuther S, Reinisch V, Straube A. Botulinum toxin type-a therapy in cluster headache: an open study. The Journal of Headache and Pain. 2007; 8: 236\u2013241.","DOI":"10.1007\/s10194-007-0400-0"},{"key":"ref78","doi-asserted-by":"crossref","unstructured":"Bagheri A, Mohammadi M, Harooni G, Khosravifard K, Feizi M, Yazdani S. Cluster Headache Associated with Secondary Unilateral Blepharospasm: a Case Report and Review of the Literature. Journal of Ophthalmic & Vision Research. 2017; 12: 225\u2013227.","DOI":"10.4103\/jovr.jovr_46_16"},{"key":"ref79","doi-asserted-by":"crossref","unstructured":"Karada\u015f O, Ozt\u00fcrk B, Ula\u015f UH, K\u00fct\u00fck\u00e7\u00fc Y, Odaba\u015f\u0131 Z. The Efficacy of Botulinum Toxin in Patients with Cervicogenic Headache: a Placebo-Controlled Clinical Trial. Balkan Medical Journal. 2012; 29: 184\u2013187.","DOI":"10.5152\/balkanmedj.2012.003"},{"key":"ref80","doi-asserted-by":"crossref","unstructured":"Hobson DE, Gladish DF. Botulinum toxin injection for cervicogenic headache. Headache. 1997; 37: 253\u2013255.","DOI":"10.1046\/j.1526-4610.1997.3704253.x"},{"key":"ref81","doi-asserted-by":"crossref","unstructured":"Padberg M, de Bruijn SFTM, Tavy DLJ. Neck pain in chronic whiplash syndrome treated with botulinum toxin. a double-blind, placebo-controlled clinical trial. Journal of Neurology. 2007; 254: 290\u2013295.","DOI":"10.1007\/s00415-006-0317-6"},{"key":"ref82","doi-asserted-by":"crossref","unstructured":"Carroll A, Barnes M, Comiskey C. A prospective randomized controlled study of the role of botulinum toxin in whiplash-associated disorder. Clinical Rehabilitation. 2008; 22: 513\u2013519.","DOI":"10.1177\/0269215507086778"},{"key":"ref83","doi-asserted-by":"crossref","unstructured":"Zirovich MD, Pangarkar SS, Manh C, Chen L, Vangala S, Elashoff DA, et al. Botulinum Toxin Type a for the Treatment of Post-traumatic Headache: a Randomized, Placebo-Controlled, Cross-over Study. Military Medicine. 2021; 186: 493\u2013499.","DOI":"10.1093\/milmed\/usaa391"},{"key":"ref84","doi-asserted-by":"crossref","unstructured":"Yerry JA, Kuehn D, Finkel AG. Onabotulinum Toxin a for the Treatment of Headache in Service Members with a History of Mild Traumatic Brain Injury: a Cohort Study. Headache. 2015; 55: 395\u2013406.","DOI":"10.1111\/head.12495"},{"key":"ref85","doi-asserted-by":"crossref","unstructured":"Lippert-Gr\u00fcner M. Botulinum toxin in the treatment of post-traumatic headache - case study. Neurologia i Neurochirurgia Polska. 2012; 46: 591\u2013594.","DOI":"10.5114\/ninp.2012.32109"},{"key":"ref86","doi-asserted-by":"crossref","unstructured":"Ivanhoe CB, Lai JM, Francisco GE. Bruxism after brain injury: successful treatment with botulinum toxin-A. Archives of Physical Medicine and Rehabilitation. 1997; 78: 1272\u20131273.","DOI":"10.1016\/S0003-9993(97)90343-9"},{"key":"ref87","doi-asserted-by":"crossref","unstructured":"MacKenzie HM, Teasell R, Miller TA, Sequeira K. Peri-Incisional Botulinum Toxin for Chronic Postcraniotomy Headache after Traumatic Brain Injury: a Case Series. PM and R. 2015; 7: 785\u2013788.","DOI":"10.1016\/j.pmrj.2015.02.015"},{"key":"ref88","doi-asserted-by":"crossref","unstructured":"Ranoux D, Martin\u00e9 G, Espagne G, Salle H, Caire F. Delayed-onset post-craniotomy headache responsive to botulinum toxin a: a case series. Acta Neurochirurgica. 2017; 159: 1375\u20131378.","DOI":"10.1007\/s00701-017-3215-z"},{"key":"ref89","doi-asserted-by":"crossref","unstructured":"Mathew PG, Cutrer FM. Injecting under pressure: the pain of low CSF pressure headache responsive to botulinum toxin injections. Current Neurology and Neuroscience Reports. 2014; 14: 477.","DOI":"10.1007\/s11910-014-0477-1"},{"key":"ref90","doi-asserted-by":"crossref","unstructured":"Garc\u00eda-Azor\u00edn D, Trigo-L\u00f3pez J, Sierra \u00c1, Blanco-Garc\u00eda L, Mart\u00ednez-P\u00edas E, Mart\u00ednez B, et al. Observational, open-label, non-randomized study on the efficacy of onabotulinumtoxinA in the treatment of nummular headache: the pre-numabot study. Cephalalgia. 2019; 39: 1818\u20131826.","DOI":"10.1177\/0333102419863023"},{"key":"ref91","doi-asserted-by":"crossref","unstructured":"Nahabet E, Janis JE, Guyuron B. Neurotoxins: Expanding Uses of Neuromodulators in Medicine\u2013Headache. Plastic and Reconstructive Surgery. 2015; 136: 104S\u2013110S.","DOI":"10.1097\/PRS.0000000000001732"}],"container-title":["Journal of Integrative Neuroscience"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.imrpress.com\/journal\/JIN\/21\/1\/10.31083\/j.jin2101037","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,27]],"date-time":"2024-11-27T15:50:28Z","timestamp":1732722628000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.imrpress.com\/journal\/JIN\/21\/1\/10.31083\/j.jin2101037"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,28]]},"references-count":91,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022]]}},"alternative-id":["S0219-6352(22)00297-2"],"URL":"https:\/\/doi.org\/10.31083\/j.jin2101037","relation":{},"ISSN":["0219-6352","1757-448X"],"issn-type":[{"value":"0219-6352","type":"print"},{"value":"1757-448X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,28]]},"article-number":"37"}}